Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists-Increasing selectivity over hERG

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 3, 2007, Pages 814-818

  Meyers, Kenneth M ^a   Kim, Nicholas ^a   Méndez Andino, José L ^a   Hu, X Eric ^a   Mumin, Rashid N ^a   Klopfenstein, Sean R ^a   Wos, John A ^a   Mitchell, Maria C ^a   Paris, Jennifer L ^a   Ackley, David C ^a   Holbert, Jerry K ^a   Mittelstadt, Scott W ^a   Reizes, Ofer ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Aminomethyl tetrahydronaphthalene biphenyl carboxamide; hERG; MCH R1 antagonists; Melanin concentrating hormone; Obesity

Indexed keywords

AMINOMETHYLTETRAHYDRONAPHTHALENE BIPHENYL CARBOXAMIDE; ANTIOBESITY AGENT; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SELECTIVITY; MOUSE; NONHUMAN; OBESITY; STRUCTURE ACTIVITY RELATION;

BIPHENYL COMPOUNDS; ERGOLINES; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INDICATORS AND REAGENTS; MIANSERIN; NAPHTHALENES; POTASSIUM CHANNEL BLOCKERS; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SOMATOSTATIN; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846253270     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.053     Document Type: Article

References (25)

1. The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity: Office of the Surgeon General, U.S Department of Health and Human Services: Rockville, MD, 2001; www.surgeongeneral.gov/topics/obesity.
2. Powell D.R. Obes. Rev. 7 (2006) 89
3. Heal D.J., Rowley H.L., and Jackson H.C. Prog. Obes. Res. 9 (2003) 260
4. Dyke H.J., and Ray N.C. Expert Opin. Ther. Patents 15 (2005) 1303
5. Carpenter A.J., and Hertzog D.L. Expert Opin. Ther. Patents 12 (2002) 1639
6. Kowalski T.J., and McBriar M.D. Expert Opin. Investig. Drugs 13 (2004) 1113
7. Receveur J.M., Bjurling E., Ulven T., Little P.B., Norregaard P.K., and Hogberg T. Bioorg. Med. Chem. Lett. 14 (2004) 5075
8. Shearman L.P., Camacho R.E., Sloan S.D., Zhou D., Bednarek M.A., Hreniuk D.L., Feighner S.D., Tan C.P., Howard A.D., Van der Ploeg L.H., MacIntyre D.E., Hickey G.J., and Strack A.M. Eur. J. Pharmacol. 475 (2003) 37
9. Kanuma K., Omodera K., Nishiguchi M., Funakoshi T., Chki S., Semple G., Tran T.-A., Kramer B., Hsu D., Casper M., Thomsen B., and Sekiguchi Y. Bioorg. Med. Chem. Lett. 15 (2005) 3853
10. Souers A.J., Gao J., Brune M., Bush E., Wodka D., Vasudevan A., Judd A.S., Mulhern M., Brodjian S., Dayton B., Shapiro R., Hernandez L.E., Marsh K.C., Sham H.L., Collins C.A., and Kym P.R. J. Med. Chem. 48 (2005) 1318
11. Ulven T., Little P.B., Receveur J.-M., Frimurer T.M., Rist Ø., Nørregaard P.K., and Högberg T. Bioorg. Med. Chem. Lett. 16 (2006) 1070
12. Palani A., Shapiro S., McBriar M.D., Clader J.W., Greenlee W.J., Spar B., Kowalski T.J., Farley C., Cook J., van Heek M., Weig B., O'Neill K., Graziano M., and Hawes B.E. J. Med. Chem. 48 (2005) 4746
13. Hu, X. E. Patent WO 2005/033063.
14. Nicholson J.R., Kohler G., Schaerer F., Senn C., Weyermann P., and Hofbauer K.G. J. Pharmacol. Exp. Ther. 317 (2006) 771
15. Tinsley F.C., Taicher G.Z., and Heiman M.L. Obes. Res. 12 (2004) 150
16. 50 determinations were carried out as described in. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., and January C.T. Biophys. J. 74 (1998) 230
17. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K.S., Strang I., Sullivan A.T., Wallis R., Camm A.J., and Hammond T.G. Cardiovasc. Res. 58 (2003) 32
18. Fernandez D., Ghanta A., Kauffman G.W., and Sanguinetti M.C. J. Biol. Chem. 279 (2004) 10120
19. Cavalli A., Poluzzi E., De Ponti F., and Recanatini M. J. Med. Chem. 45 (2002) 3844
20. Sanguinetti M.C., and Mitcheson J.S. Trends Pharmacol. Sci. 26 (2005) 119
21. Dai-Ho G., and Mariano P.S. J. Org. Chem. 5 (1988) 5113
22. Szewczyk J.R., and Sternbach D.D. Curr. Med. Chem.: Immunol. Endocr. Metab. Agents 5 (2005) 73 and references therein
23. i) and maximal efficacy were determined and used to define structure-activity relationship.
24. 3H] mesulergine and excess 10 μM mianserin (ICN). After incubating the mixture at room temperature for 60 min, bound mesulergine was separated from unbound mesulergine by filtration through glass fiber B filter (GF/B) plates (Millipore). Bound radioactive mesulergine was detected using a scintillation counter.
25. Bilodeau M.T., Balitza A.E., Koester T.J., Manley P.J., Rodman L.D., Buser-Doepner C., Coll K.E., Fernandes C., Gibbs J.B., Heimbrook D.C., Huckle W.R., Kohl N., Lynch J.J., Mao X., McFall R.C., McLoughlin D., Miller-Stein C.M., Rickert K.W., Sepp-Lorenzino L., Shipman J.M., Subramanian R., Thomas K.A., Wong B.K., Yu S., and Hartman G.D. J. Med. Chem. 47 (2004) 6363